Plasmalogens and Alzheimer’s disease: a review
Abstract Growing evidence suggests that ethanolamine plasmalogens (PlsEtns), a subtype of phospholipids, have a close association with Alzheimer’s disease (AD). Decreased levels of PlsEtns have been commonly found in AD patients, and were correlated with cognition deficit and severity of disease. Li...
Main Authors: | Xiao Q. Su, Junming Wang, Andrew J. Sinclair |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12944-019-1044-1 |
Similar Items
-
Plasmalogen Improves Memory Function by Regulating Neurogenesis in a Mouse Model of Alzheimer’s Diseases
by: Rongzi Li, et al.
Published: (2023-07-01) -
Plasmalogen Replacement Therapy
by: José Carlos Bozelli, et al.
Published: (2021-10-01) -
Editorial: Solving the plasmalogen puzzle—From basic science to clinical application
by: Fabian Dorninger, et al.
Published: (2023-01-01) -
Regulation of plasmalogen metabolism and traffic in mammals: The fog begins to lift
by: Fabian Dorninger, et al.
Published: (2022-08-01) -
EPA enriched ethanolamine plasmalogens significantly improve cognition of Alzheimer’s disease mouse model by suppressing β-amyloid generation
by: Hongxia Che, et al.
Published: (2018-02-01)